Rabbani F. Use of erythropoetin in treatment of early anemia of premature infants.

The terms of the development of early anemia of premature infants (EAI), clinico-haematologic features of early anemia of premature infants have been fixed in dissertation. It was grounded administered high doses of recombinant human erythropoetin (rHuEPO). We think EAI to be a result of features of adaptation of the period of birth of premature infant, it occurs in 73,9 % children within the first month of the life, and in 26,1 % - after the first month. Presence of "physiologic anizocytose" and great volumetric erythrocytes with a high content of hemoglobin appears to be a peculiarity of this kind of anemia. Disorders of peripheral haemodynamics as paleness of dermal integuments, palms of the hands, transparence of lobules of the ears, lowering of moving activity. Use ofRhEP in the dosage 400 unites/kg per a weak, i.g. 1200 un/kg is a ground for treating EAI. Use of rHuEPO did not revealed any side effects. It is possible to say about some lengthening of the terms of physiological loss of child bodymass.